Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 25, 2023 09:07 ET | Source: ZyVersa Therapeutics

ZyVersa Therapeutics Announces a Publication in Frontiers in Medicine Showing Direct Inflammasome Activation in Children with Juvenile Idiopathic Arthritis

Juvenile idiopathic arthritis (“JIA”), a complex autoimmune inflammatory disorder, is the most common childhood chronic rheumatic diseaseThis is the first report documenting inflammasome activation in...
May 19, 2023 16:15 ET | Source: ZyVersa Therapeutics

ZyVersa Therapeutics Announces Changes to ZyVersa’s Board of Directors

WESTON, Fla., May 19, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for the...
May 15, 2023 09:07 ET | Source: ZyVersa Therapeutics

ZyVersa Therapeutics Announces Article Published in Metabolism Pointing to Glomerular Cholesterol Accumulation as Key Factor Exacerbating Renal Injury and Dysfunction in Diabetic Kidney Disease

Published data demonstrate that a deficiency in cholesterol transporter ABCA1 increases deposition of cellular cholesterol, contributing to inflammation, cell death (apoptosis), and damage to the...
May 12, 2023 09:07 ET | Source: ZyVersa Therapeutics

ZyVersa Therapeutics Reports First Quarter 2023 Corporate and Financial Results

Key Highlights: Continued progress has been made in advancing an investigator-initiated clinical trial to gain human proof-of-concept for Cholesterol Efflux Mediator™ VAR 200 in patients with renal...
May 11, 2023 09:07 ET | Source: ZyVersa Therapeutics

ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in A.G.P.’s Virtual Healthcare Conference

ZyVersa is advancing a dynamic pipeline of drug candidates with multiple programs built around two proprietary technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment of kidney diseases, and...
May 09, 2023 09:05 ET | Source: ZyVersa Therapeutics

ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2023 BIO International Convention

ZyVersa is advancing a dynamic pipeline of drug candidates with multiple programs built around two proprietary technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment of kidney diseases, and...
May 04, 2023 09:07 ET | Source: ZyVersa Therapeutics

ZyVersa Therapeutics Announces a Publication in Hepatology Revealing That Alcohol-induced Extracellular ASC Specks Perpetuate Liver Inflammation and Damage in Alcoholic Hepatitis

Prolonged systemic inflammation contributes to poor clinical outcomes in severe alcohol-associated hepatitis (“AH”) even after cessation of alcohol useReported data demonstrate a central role of NLRP3...
May 01, 2023 18:30 ET | Source: ZyVersa Therapeutics

ZyVersa Therapeutics, Inc. Announces Closing of $11.0 Million Public Offering

WESTON, Fla., May 01, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for...
April 27, 2023 09:07 ET | Source: ZyVersa Therapeutics

ZyVersa Therapeutics' CEO, Stephen C. Glover, to Present at Sidoti Micro-Cap Virtual Conference

Mr. Glover to discuss key updates on the development status of ZyVersa’s Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200 for renal disease and Inflammasome ASC Inhibitor IC 100 for numerous CNS...
April 26, 2023 09:10 ET | Source: ZyVersa Therapeutics

ZyVersa Therapeutics, Inc. Announces Pricing of $11.0 Million Public Offering

WESTON, Fla., April 26, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for...